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Abstract: 22 
Background: Central adjudication of stroke type is commonly implemented in large multicentre 23 
clinical trials. We investigated the effect of central adjudication of diagnosis of stroke type at trial entry 24 
in the Efficacy of Nitric Oxide in Stroke (ENOS) trial. 25 
Methods: ENOS recruited patients with acute ischaemic or haemorrhagic stroke, and diagnostic 26 
adjudication was carried out using cranial scans. For this study, diagnoses made by local site 27 
clinicians were compared with those by central, masked adjudicators using kappa statistics. The trial 28 
primary analysis and subgroup analysis by stroke type were re-analysed using stroke diagnosis made 29 
by local clinicians, and simulations were used to assess the impact of increased non-differential 30 
misclassification and subgroup effects. 31 
Results: Agreement on stroke type (Ischaemic, Intracerebral Haemorrhage, Unknown stroke type, 32 
No-stroke) was high (κ=0.92). Adjudication of stroke type had no impact on the primary outcome or 33 
subgroup analysis by stroke type. With misclassification increased to 10 times the level observed in 34 
ENOS and a simulated subgroup effect present, adjudication would have affected trial conclusions. 35 
Conclusions: Stroke type at trial entry was diagnosed accurately by local clinicians in ENOS. 36 
Adjudication of stroke type by central adjudicators had no measurable effect on trial conclusions. 37 
Diagnostic adjudication may be important if diagnosis is complex and a treatment-diagnosis 38 
interaction is expected. 39 
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Introduction 46 
Clinical trials in acute stroke often recruit many thousands of participants making them complex, 47 
lengthy, and expensive. In many stroke trials, key endpoints, adverse events, or diagnoses qualifying 48 
for trial entry are adjudicated by independent experts. Independent, central adjudication may be 49 
conducted by one individual or a panel of experts, who may work independently or convene as a 50 
committee, with agreed procedures for assigning definitive values, usually blinded to treatment 51 
allocation whenever possible(1). The adjudication procedure is believed to protect against bias 52 
resulting from differential misclassification(2, 3), and to improve precision of treatment estimates by 53 
reducing ‘noise’ from random errors. This is especially important in trials where events are rare, in 54 
which a small degree of misclassification can have a large impact on study findings(2, 3) or where the 55 
event is subjective such as some clinical diagnoses. Adjudication also introduces a level of quality 56 
control to detect poorly trained or performing investigators. 57 
Central adjudication is commonly included in cardiovascular studies(4, 5), with conflicting evidence as 58 
to the value of adjudication of endpoints(6-13) compared with simply using endpoints assigned by local 59 
clinicians or investigators at participating research sites. There is little research evidence regarding 60 
the importance of diagnostic adjudication, where diagnosis is not used as an endpoint, but is used to 61 
diagnose patients at trial entry. Diagnoses made at trial entry can be used to define eligibility, as a 62 
stratification or minimisation factor, as a covariate in a regression model, or to specify categories in a 63 
subgroup analysis.  64 
Stroke is a clinical diagnosis that can be further subclassified based on the results of further 65 
investigations, including brain and vessel imaging and cardiac examinations. Given the complex 66 
nature of stroke subtypes(14), stroke diagnoses are commonly adjudicated by independent experts in 67 
clinical trials. Ninomiya et al.(11) found that adjudication of stroke type and cause of death as study 68 
endpoints had no substantive impact on treatment effect estimates in their trial. However, stroke 69 
diagnosis was an endpoint, rather than a criterion for inclusion. While adjudication of endpoints has 70 
the greatest potential to influence trial results and therefore has received greatest attention as to its 71 
value, misclassification of entry criteria might also introduce bias, affect the precision of effect 72 
estimates or reduce statistical power(15). However, we are not aware of any such investigation of the 73 
value of central adjudication of the diagnosis qualifying for trial inclusion. 74 
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The aim of this study was to investigate the value of central adjudication of stroke type at trial entry in 75 
a secondary analysis of a large acute stroke trial. The three objectives were to: (1) compare stroke 76 
diagnoses made by local clinicians and central masked adjudicators; (2) assess the impact of 77 
adjudication on the primary analysis and the subgroup analysis by stroke type; (3) using simulation, 78 
explore the effects of increasing levels of misclassification of diagnosis and introducing a subgroup 79 
effect by stroke type on analyses. 80 
 81 
Materials and Methods 82 
Efficacy of Nitric Oxide in Stroke (ENOS) Trial 83 
The Efficacy of Nitric Oxide in Stroke (ENOS) trial examined the safety and efficacy of glyceryl 84 
trinitrate (GTN) versus no GTN in patients with acute ischaemic or haemorrhagic stroke. Independent 85 
expert assessors, referred to in this paper as adjudicators, who were masked to treatment allocation, 86 
centrally assessed CT and MRI scans to inform diagnosis of stroke type. The primary outcome was 87 
functional outcome after stroke, measured using the modified Rankin Scale (mRS) at day 90 by 88 
outcome assessors who were masked to treatment allocation. The trial recruited 4011 patients from 89 
173 sites, across 23 countries on five continents. The primary outcome was analysed using ordinal 90 
logistic regression, and the adjusted common odds ratio (OR) for worse outcome with GTN versus no 91 
GTN was 1·01 (95% CI 0·91 to 1·13; p=0·83). The protocol, statistical analysis plan, and main results 92 
for ENOS have been described in detail elsewhere(16-18). 93 
 94 
Diagnosis of Stroke Type 95 
After enrolment into the ENOS trial, all participants had a CT (or MRI) scan at baseline or within 96 
seven days (referred to as baseline scan), and if possible again after seven days (referred to as 97 
follow-up scan) to assess evolution of the stroke lesion. Each scan was analysed by local clinicians, 98 
who then used information from the baseline scan, follow-up scan if available, input from the local 99 
radiology team, and clinical history and assessment of the participant between admission and 100 
discharge, in order to assign a clinical diagnosis for each participant (referred to as Local clinician 101 
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diagnosis). The following diagnoses were made: Ischaemic stroke, intracerebral haemorrhage, 102 
unknown stroke and no stroke. All scans were then sent electronically to the central trial team.  103 
A team of independent, central adjudicators, masked to treatment allocation and Local clinician 104 
diagnosis, assessed all brain scans. They recorded their assessment using a specially designed 105 
questionnaire that captured information on the presence of stroke, haemorrhage, occluded arteries, 106 
Alberta stroke program early CT score(19), mass effect, white matter disease, atrophy, and other 107 
visible lesions. This information was used to determine an adjudicator diagnosis of stroke type for 108 
both baseline and follow-up scans. A final diagnosis of stroke type for each participant (referred to as 109 
Central adjudication diagnosis) was assigned using an algorithm that assessed whether diagnoses 110 
from local clinicians and adjudicators sufficiently agreed, otherwise stroke diagnosis was allocated on 111 
a case-by-case basis. 112 
Central adjudication diagnosis was assigned using all available information from both local clinicians 113 
and adjudicators, and was thus considered in this study as the ‘gold standard’. Local clinician 114 
diagnosis represents the diagnosis of stroke type in ENOS if no central adjudication had taken place. 115 
In the ENOS analyses, stroke type at trial entry was included in between-group comparisons as a 116 
baseline covariate, and as a subgroup variable to investigate any differential effects of the 117 
interventions according to stroke type. The main ENOS analyses used Central adjudication diagnosis 118 
of stroke. The analyses presented here compared the main ENOS analyses with analyses conducted 119 
using Local clinician diagnosis of stroke, thus allowing an investigation into the value of adjudication 120 
of a baseline variable in ENOS.    121 
 122 
Simulated misclassification of stroke type and simulated subgroup effect  123 
Statistical simulations were created to: (1) increase the extent of misclassification of Local clinician 124 
diagnosis of stroke compared with the gold standard Central adjudication diagnosis; (2) introduce an 125 
interaction (subgroup effect) between ENOS treatment arm and stroke type. These simulations 126 
enabled us to investigate the effects of misclassification on the ENOS primary analysis and on 127 
subgroup analysis, for both the subgroup effect observed in ENOS and for a subgroup effect 128 
introduced by simulation. The magnitude of the treatment-stroke type interaction was increased in 129 
simulation as there was no statistical evidence of a subgroup effect in the observed ENOS dataset. 130 
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In simulated datasets, the misclassification of Local clinician diagnosis observed in ENOS was 131 
increased by factors of 3, 5, 10, 15 and 20 (referred to as SX3, SX5, SX10, SX15 and SX20 132 
respectively). We also introduced a subgroup effect by reducing mRS score by 1 point for 10% of 133 
participants with an Ischaemic stroke, and increasing mRS score by 1 point for 30% of participants 134 
with an Intracerebral Haemorrhage, with mRS scores for all participants constrained to be in the 135 
normal range 0 to 6. All participants with an altered mRS score were in the GTN arm of the trial. For 136 
more detailed simulation methods, please consult Supplementary File S1. 137 
 138 
Statistical Methods 139 
Categorical variables were described using N (%). Observed agreement between Local clinician and 140 
Central adjudication diagnoses was quantified using unweighted kappa statistics. 141 
Using observed ENOS data, the effect of GTN treatment on mRS score was estimated as in the 142 
ENOS trial main report, using ordinal logistic regression models, adjusted for stratification and 143 
minimisation variables. Models including Local clinician and Central adjudication diagnosis of stroke 144 
type as a covariate were fitted separately and the estimated effects of GTN treatment from the two 145 
models were compared using a test of homogeneity. Similarly, subgroup effects were estimated by 146 
fitting an interaction term between GTN treatment and stroke type according to either Local clinician 147 
or Central adjudication diagnosis. 148 
The primary trial analysis was then repeated using each simulated level of Local clinician diagnosis 149 
misclassification (SX3 to SX20). The subgroup analysis was also repeated for each simulated level of 150 
Local clinician diagnosis misclassification for both the subgroup effect observed in the ENOS dataset, 151 
and for the increased subgroup effect created using simulation. Regression model coefficients and 152 
standard errors are presented on the log scale for ease of comparison. 153 
 154 
Results 155 
Of 4011 participants randomised, 3857 (96%) and 1025 (26%) had baseline and follow up scans 156 
respectively that were assessed by adjudicators. A total of 35 participants had a missing Local 157 
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clinician diagnosis, and all participants had a Central adjudication diagnosis assigned after the 158 
combined information from the hospital and central adjudicators was reviewed (Figure 1). 159 
The proportion of participants with each stroke type was similar for those that did or did not have a 160 
follow-up scan, indicating no evidence of bias in the selection of participants for a follow up scan and 161 
therefore having more information with which to assign a diagnosis (see Supplementary File, S2).  162 
Agreement was high in ENOS, with local clinicians and central adjudicators agreeing on 79% of 163 
diagnoses at baseline. There was excellent agreement between Local clinician and Central 164 
adjudication diagnoses (crude agreement 98%, unweighted kappa, κ=0.92) for the 3976 (99%) 165 
participants who could be included in this analysis (Table 1).  166 
Misclassification of Local clinician diagnosis resulted in kappa statistics for agreement between 167 
Central adjudication and Local clinician diagnoses of 0.78, 0.67, 0.46, 0.32 and 0.21 for SX3-SX20 168 
respectively. As expected due to strong agreement between Central adjudication and Local clinician 169 
diagnoses of stroke type, it made little difference which one was used as a covariate in the primary 170 
analysis of observed ENOS data (p-value for homogeneity p=0.95, see Supplementary File, S3). 171 
Similarly, coefficients and standard errors for the interaction between GTN and stroke type were very 172 
similar regardless of whether Local clinician or Central adjudication diagnosis of stroke type was used 173 
(data not shown). 174 
Increased levels of non-differential misclassification of stroke diagnosis introduced by simulation 175 
made no material difference to the estimated treatment effect of GTN or the precision of the estimate 176 
(Table 2). Table 3 shows the effect of GTN separately for each stroke type using the magnitude of 177 
subgroup effect observed in the ENOS data, and where non-differential misclassification of stroke 178 
type is increased by simulation. The number of participants diagnosed with ischaemic stroke 179 
decreased, whilst each of the other types of stroke increased, respectively, with increasing 180 
misclassification. The effects of misclassification on stroke-specific estimates of GTN treatment were 181 
not wholly consistent, although increasing misclassification tended to give treatment effects closer to 182 
zero and standard errors that increased or decreased inversely with stroke-specific sample size 183 
accordingly.  184 
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Simulation of a subgroup effect, whereby GTN was beneficial among participants with an ischaemic 185 
stroke, and harmful among participants with a haemorrhagic stroke, attenuated the treatment effects 186 
even further (Table 4). After stroke type was increasingly misclassified using simulation, statistical 187 
evidence of a subgroup effect was reduced and the effects of subgroup sample size on precision 188 
were as expected (Tables 4 and 5).   189 
 190 
Discussion 191 
Misclassification of stroke type by local trial site clinicians was low, with excellent agreement found 192 
between the Central adjudication and Local clinician diagnosis. Due to the level of agreement, there 193 
was little impact of adjudication of stroke type at trial entry on the primary analysis or subgroup 194 
analysis of ENOS. Increased levels of non-differential misclassification produced little change in the 195 
primary outcome. After simulating a strong subgroup effect by stroke type, increased misclassification 196 
resulted in reduction of the subgroup effect, suggesting that in this situation adjudication may be 197 
important to ensure robust results.  198 
In ENOS, due to blinding, differential misclassification of stroke type was unlikely, which was why we 199 
introduced non-differential misclassification using simulation. Even with non-differential 200 
misclassification increased by 20 times the observed level, there was little effect on both the primary 201 
and subgroup analyses. Only when a substantial subgroup effect (p<0.01) and marked 202 
misclassification of stroke diagnosis by local investigators were simulated would adjudication have 203 
resulted in differing conclusions. These extreme, and thus arguably unlikely, conditions before central 204 
adjudication is seen to add value are likely due to the fact that in our analyses, diagnosis of stroke 205 
type is a baseline variable rather than a study endpoint. However a recent Cochrane review(20) that 206 
assessed endpoint adjudication of subjective binary events across a range of clinical areas, including 207 
47 RCTs, also found that adjudication did not affect the treatment effect estimates (Ratio of Odds 208 
Ratios: 1.00, 95% C.I: [0.97 to 1.04]). The review suggested that adjudication ‘may be most important 209 
when onsite assessors are not blinded and the risk of misclassification is high’.  210 
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It is worth noting that in ENOS, diagnostic adjudication was used for purposes in addition to informing 211 
the diagnosis. The adjudication process provided a large amount of extra information which hospital 212 
scan results would not have recorded. This information can be used to carry out imaging-based 213 
subgroup analyses or help to improve any subsequent sub-studies. Furthermore, the central 214 
adjudication process meant that each scan had been rated using a central, standard approach, 215 
enabling data to be pooled with other trials that have used a similar method. Therefore, the ENOS 216 
data can be utilised further, alongside existing data, to provide a larger sample size to test the 217 
independent prognostic value and potential treatment implications of the scan signs raised in various 218 
studies, as well as assisting in confirming or refuting ideas about not treating certain types of infarct or 219 
effects on infarct swelling.   220 
The diagnostic adjudication process in ENOS resulted in increased complexity, and monetary and 221 
time costs. These included payments to adjudicators, resources associated with handling adjudicator 222 
data (data entry, database programming, and statistical analysis), the time taken by the trial team to 223 
determine the trial diagnosis, and data queries. Although this is the first study we are aware of to 224 
investigate diagnostic adjudication in stroke trials, where diagnosis is not used as an endpoint, 225 
previous studies which have looked at adjudication of endpoints have found similar conclusions. 226 
Slight benefits of improving accuracy and reducing misclassification were outweighed by the cost and 227 
complications introduced by an adjudication committee(2, 11). However, there may be some 228 
unmeasurable benefits of an adjudication process, and adjudication could have indirectly 229 
strengthened local assessment due to a policing effect. This effect could have resulted in improved 230 
site performance as investigators would have been aware that diagnoses would have been checked 231 
centrally, and thus perform more carefully.    232 
One strength of this study is that we used a large, well conducted, randomised trial to provide data 233 
from over 4000 participants for analysis. Furthermore, the data completeness was extremely high, 234 
minimising the risk of bias due to partially completed data. The simulation undertaken in this study 235 
allowed an investigation into the robustness of observed results to more extreme data scenarios. This 236 
was important to understand how adjudication of diagnosis at trial entry could affect a similar trial 237 
where agreement was not as good as observed in ENOS. This approach, using a combination of 238 
10 
 
observed and simulated data, can be readily applied to secondary analyses of other trials, notably on 239 
outcome variables as well as baseline variables, in order to inform future studies. 240 
A limitation of this study is that the potential for adjudication to have an important effect is likely to be 241 
less for a baseline variable, as seen in ENOS, rather than a primary outcome as in Ninomiya et al.(11). 242 
Therefore, we also looked into the impact of adjudication on subgroup analyses involving stroke type, 243 
to allow a thorough investigation into the value of central adjudication of a baseline variable had on 244 
ENOS. Furthermore, the treatment estimates for GTN for both ischaemic and haemorrhagic stroke 245 
were similar, so increased misclassification in this situation had limited impact, although this may not 246 
be the case in other studies where there is a treatment-diagnosis interaction. Simulation allowed us to 247 
explore this setting, but a further investigation using data from another large trial would be beneficial 248 
to reinforce our findings. 249 
 250 
Conclusions 251 
This study found that clinicians at ENOS trial sites largely were correct in their diagnosis of stroke and 252 
adjudication did not impact on the trial results. Adjudication of stroke type at trial entry would have 253 
altered conclusions had there been strong evidence of a subgroup effect by stroke type, and where 254 
misclassification was at least ten times that observed in ENOS. In pilot or feasibility studies, 255 
misclassification could be estimated in order to inform whether adjudication would be useful in that 256 
particular trial. Researchers should consider the value adjudication could bring to their study before its 257 
implementation in a clinical trial to avoid wasted time and unneeded expenditure.  258 
 259 
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Supplementary Files 356 
File name: File S1 357 
Title of data: S1 – Simulation methods 358 
Description of data: Detailed description of the simulation process used in this study, including how 359 
the simulated datasets were generated, how misclassification was increased and how the number of 360 
simulations was calculated. 361 
File name: File S2 362 
Title of data: S2 - Supplementary Table 1 363 
Description of data: Table which shows the diagnosis of stroke type made by the adjudicators for all 364 
scans that were assessed. This table is further split for participants that did and did not have a follow 365 
up scan available, which show that adjudicator’s diagnoses were similar for those participants that did 366 
and did not receive a follow up scan. 367 
File name: File S3 368 
Title of data: S3 – Supplementary Table 2 369 
Description of data: Table which shows the primary outcome measure for ENOS and how this result 370 
would be affected with and without adjudication. A p-value for homogeneity is given which tests the 371 
null hypothesis that the estimates from both analyses are the same. 372 
  373 
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Tables and Figures Legends: 374 
Figure 1: Flow diagram showing diagnosis of stroke type in ENOS 375 
Table 1: Agreement between Local clinician and Central adjudication diagnosis 376 
Table 2: Effect of increased misclassification of stroke type at trial entry on ENOS primary analysis 377 
Table 3: Effect of misclassification of stroke type at trial entry on subgroup analysis: based on 378 
subgroup effect observed in ENOS data 379 
Table 4: Effect of misclassification of stroke type on subgroup analysis: based on simulated subgroup 380 
effect 381 
Table 5: P-values for interaction tests between GTN and stroke type based on observed and 382 
simulated ENOS data 383 
 384 
  385 
17 
 
Tables: 386 
Table 1: Agreement between Local clinician and Central adjudication diagnosis 387 
Central adjudication diagnosis 
Local clinician 
diagnosis 
Ischaemic Intracerebral 
Haemorrhage 
Unknown 
stroke type 
No-stroke Total 
Ischaemic 3233 6 0 0 3239 
Intracerebral 
Haemorrhage 
18 615 0 1 634 
Unknown stroke 
type 
63 0 0 0 63 
No-stroke 2 2 0 36 40 
Total 3316 623 0 37 3976 
Crude agreement = 3884/3976 = 98% 388 
Unweighted kappa = 0.92 389 
  390 
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Table 2: Effect of increased misclassification of stroke type at trial entry on ENOS 391 
primary analysis  392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
 405 
SX3-SX20 refer to the misclassified Local clinical diagnoses. Kappa statistics showing the agreement 406 
between each diagnosis and Central adjudication diagnosis are 0.78, 0.67, 0.46, 0.32 and 0.21 for 407 
SX3-SX20 respectively. 408 
  409 
Source of diagnosis of 
stroke type at trial 
entry 
Results from regression 
model comparing effect of 
GTN versus no GTN 
 Log OR SE log OR 
Central adjudication -0.02473 0.05565 
SX3 -0.02446 0.05563 
SX5 -0.02426 0.05563 
SX10 -0.02426 0.05561 
SX15 -0.02411 0.05561 
SX20 -0.02415 0.05561 
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Table 3: Effect of misclassification of stroke type at trial entry on subgroup analysis: 410 
based on subgroup effect observed in ENOS data  411 
Stroke Type Source of diagnosis of 
stroke type at trial entry 
N Subgroup-specific estimated 
effect of GTN versus no GTN 
   Log OR SE log OR 
Ischaemic Central adjudication 3338 -0.03048 0.06085 
 SX3 3096 -0.03114 0.06003 
 SX5 2935 -0.02953 0.06491 
 SX10 2531 -0.02503 0.06987 
 SX15 2129 -0.03130 0.07618 
 SX20 1725 -0.03043 0.08476 
 
Haemorrhagic Central adjudication 623 0.02699 0.14110 
 SX3 657 0.02761 0.13717 
 SX5 682 0.01898 0.13474 
 SX10 739 0.01443 0.12943 
 SX15 798 -0.00496 0.12456 
 SX20 855 0.00832 0.12027 
 
Unknown Central adjudication 1 -  
 SX3 196 0.00091 0.25320 
 SX5 325 -0.01070 0.19592 
 SX10 652 -0.03348 0.13830 
 SX15 975 -0.00867 0.11286 
 SX20 1302 -0.02353 0.09743 
 
No-stroke Central adjudication 38 0.18475 0.65491 
 SX3 51 0.16043 0.54100 
 SX5 58 0.05159 0.48825 
 SX10 78 -0.00907 0.40673 
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 SX15 98 -0.00359 0.36080 
 SX20 118 -0.00448 0.32877 
Simulations produced datasets containing 4000 observations.  412 
SX3-SX20 refer to the misclassified Local clinical diagnoses. Kappa statistics showing the agreement 413 
between each diagnosis and Central adjudication diagnosis are 0.78, 0.67, 0.46, 0.32 and 0.21 for 414 
SX3-SX20 respectively. 415 
  416 
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Table 4: Effect of misclassification of stroke type on subgroup analysis: based on 417 
simulated subgroup effect  418 
Stroke Type Source of diagnosis of 
stroke type at trial entry 
N Subgroup-specific estimated 
effect of GTN versus no GTN 
   Log OR SE log OR 
Ischaemic Central adjudication 3338 -0.14122 0.06085 
 SX3 3096 -0.13885 0.06320 
 SX5 2935 -0.13576 0.06493 
 SX10 2531 -0.12591 0.06988 
 SX15 2129 -0.11477 0.07624 
 SX20 1725 -0.11388 0.08478 
 
Haemorrhagic Central adjudication 623 0.29183 0.14156 
 SX3 657 0.25154 0.13760 
 SX5 682 0.22485 0.13522 
 SX10 739 0.17519 0.12990 
 SX15 798 0.11796 0.12482 
 SX20 855 0.08150 0.12015 
 
Unknown Central adjudication 1 -  
 SX3 196 -0.09800 0.25358 
 SX5 325 -0.12723 0.19472 
 SX10 652 -0.15382 0.13795 
 SX15 975 -0.13565 0.11250 
 SX20 1302 -0.12854 0.09744 
 
No-stroke Central adjudication 38 0.25680 0.68781 
 SX3 51 0.14555 0.53944 
 SX5 58 0.05832 0.49047 
 SX10 78 0.07533 0.40879 
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 SX15 98 -0.05162 0.36561 
 SX20 118 0.02436 0.33095 
Simulations produced datasets containing 4000 observations.  419 
SX3-SX20 refer to the misclassified Local clinical diagnoses. Kappa statistics showing the agreement 420 
between each diagnosis and Central adjudication diagnosis are 0.78, 0.67, 0.46, 0.32 and 0.21 for 421 
SX3-SX20 respectively. 422 
 423 
  424 
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Table 5: P-values for interaction tests between GTN and stroke type based on 425 
observed and simulated ENOS data  426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
SX3-SX20 refer to the misclassified Local clinical diagnoses. Kappa statistics showing the agreement 449 
between each diagnosis and Central adjudication diagnosis are 0.78, 0.67, 0.46, 0.32 and 0.21 for 450 
SX3-SX20 respectively. 451 
 452 
 453 
Data source Source of 
diagnosis 
Median p-value from 100 
simulated analyses (IQR) 
Subgroup effect based 
on observed ENOS 
data 
Central 
adjudication 
0.38592 (0.17160, 0.61673) 
 SX3 0.39858 (0.15347, 0.65161) 
 SX5 0.46350 (0.16563, 0.72459) 
 SX10 0.43609 (0.22501, 0.78923) 
 SX15 0.54638 (0.32173, 0.79183) 
 SX20 0.46829 (0.23353, 0.70323) 
Subgroup effect based 
on simulated ENOS 
data 
Central 
adjudication 
0.00882 (0.00096, 0.06394) 
 SX3 0.02801 (0.00699, 0.14882) 
 SX5 0.04675 (0.00677, 0.24457) 
 SX10 0.10912 (0.01997, 0.31892) 
 SX15 0.16117 (0.05030, 0.47707) 
 SX20 0.24764 (0.06521, 0.54910) 
